Significant hypercalciuria with unexpected outcome
HTML (Español (España))
PDF (Español (España))


Multiple myeloma
Calcium Metabolism Disorders
Osteoporotic Fractures
Bone Diseases

How to Cite

Pinzon Tovar, A., Oviedo Cali, M., Jimenez-Salazar, S., Mendez, H., & Buitrago-Toro, K. . (2023). Significant hypercalciuria with unexpected outcome. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 10(2).


Background: Osteoporosis is the most prevalent bone endocrine disorder in older adults with high morbidity and mortality worldwide. Secondary causes in men represent between 50 to 80% of cases. In the initial approach, the study of calcium metabolism is important.

Purpose: To present the case report of a patient with secondary osteoporosis and normocalcemia associated with significant hypercalciuria.

Case presentation: 55-year-old male patient, with a history of nephrolithiasis, who consulted for low back pain, and in whom vertebral fractures due to fragility at the thoracic and lumbar level were documented. A diagnosis of severe osteoporosis was made and bone densitometry suggested a secondary cause, ultimately confirming the presence of multiple myeloma.

Discussion and conclusion: Osteoporosis must be considered in fragility fractures scenario. in males, almost 80% of cases have a secondary cause. Hypercalciuria is a rare disorder that should always be characterized. Extreme high values of erythrocyte sedimentation rate (ESR) ??always have pathological significance, especially in relation to diseases that generate a high inflammatory load.
HTML (Español (España))
PDF (Español (España))


Orjuela AM, Olarte ÓR, Plata PN, Escobar FS, Choueka MC, Reyes MÁ, et al. II Consenso colombiano para el manejo de la osteoporosis posmenopáusica. Rev Colomb Reumatol. 2018;25(3):184-210.

Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull. 2020;133(1):105-17.

Rebolledo BJ, Unnanuntana A, Lane JM. A comprehensive approach to fragility fractures. J Orthop Trauma. 2011;25(9):566-73.

Soriano R, Herrera S, Nogués X, Diez-Perez A. Current and future treatments of secondary osteoporosis. Best Pract Res Clin Endoc Metab. 2014;28(6):885-94.

Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary Osteoporosis. Endoc Rev. 2022;43(2):240-313.

Stein E, Shane E. Secondary osteoporosis. Endoc Metab Clin. 2003;32(1):115-34.

Allen S, Forney-Gorman A, Homan M, Kearns A, Kramlinger A, Sauer M. Diagnosis and treatment of osteoporosis. Assessment. 2017.

Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. Eur J Endoc. 2010;162(6):1009-20.

Figueres L, Hourmant M, Lemoine S. Understanding and managing hypercalciuria in adults with nephrolithiasis: keys for nephrologists. Nephrol Dial Transplant. 2020;35(4):573-5.

Audran M, Legrand E. Hypercalciuria. Joint Bone Spine. 2000;67(6):509-15.

Arrabal-Polo M, Girón-Prieto MS, Orgaz-Molina J, Zuluaga-Gómez A, Arias-Santiago S, Arrabal-Martín M. Litiasis renal cálcica y densidad mineral ósea. Importancia del metabolismo óseo en la litiasis urinaria. Actas Urol Esp. 2013;37(6):362-7.

Daniels LM, Tosh PK, Fiala JA, Schleck CD, Mandrekar JN, Beckman TJ. Extremely Elevated Erythrocyte Sedimentation Rates: Associations With Patients' Diagnoses, Demographic Characteristics, and Comorbidities. Mayo Clin Proc. 2017;92(11):1636-43.

Sella S, Cattelan C, Realdi G, Giannini S. Bone disease in primary hypercalciuria. Clin Cases Miner Bone Metab. 2008;5(2):118.

García Nieto VM, Luis Yanes MI, Tejera Carreño P, Perez Suarez G, Moraleda Mesa T. The idiopathic hypercalciuria reviewed. Metabolic abnormality or disease? Nefrología. 2019;39(6):592-602.

Pak CY, Kaplan R, Bone H, Townsend J, Waters O. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. New Eng J Med. 1975;292(10):497-500.

West S, Kolfenbach J. Rheumatology Secrets E-Book. Elsevier Health Sciences: Amsterdam, The Netherlands; 2019.

Kaufman JM, Lapauw B, Goemaere S. Current and future treatments of osteoporosis in men. Best Prac Res Clin Endoc Metab. 2014;28(6):871-84.

Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocr Metab. 2018;103(5):1715-44.

Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocr Metab. 2012;97(5):1508-16.

John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, et al. Most multiple myeloma patients have low testosterone. Leuk Lymphoma. 2019;60(3):836-8.

Gaudio A, Xourafa A, Rapisarda R, Zanoli L, Signorelli SS, Castellino P. Hematological diseases and osteoporosis. Int J Mol Sci. 2020;21(10):3538.

Rajkumar SV, Kumar S, editores. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc; 2016: Elsevier.

Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al., editores. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc.; 2003: Elsevier.

Sobh MM, Abdalbary M, Elnagar S, Nagy E, Elshabrawy N, Abdelsalam M, et al. Secondary Osteoporosis and Metabolic Bone Diseases. J Clin Med. 2022;11(9).

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.